OCTREOSCAN (indium in -111 pentetreotide) by Curium Pharma is clinical pharmacology general pentetreotide is a dtpa conjugate of octreotide, which is a long-acting analog of the human hormone, somatostatin. First approved in 1994.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
OCTREOSCAN (Indium In-111 Pentetreotide) is a diagnostic imaging agent that binds to somatostatin receptors on neuroendocrine tumors and receptor-rich normal tissues. It is a radiolabeled octreotide analog conjugated to DTPA that concentrates in tumors within one hour of injection, enabling visualization after background clearance. The agent is used to localize somatostatin receptor-expressing neuroendocrine tumors for diagnostic and staging purposes.
Product is in late-stage lifecycle with approaching loss of exclusivity, indicating team focus on transition strategy and retention against generic/biosimilar competition.
CLINICAL PHARMACOLOGY General Pentetreotide is a DTPA conjugate of octreotide, which is a long-acting analog of the human hormone, somatostatin. Indium In 111 pentetreotide binds to somatostatin receptors on cell surfaces throughout the body. Within an hour of injection, most of the dose of indium…
Worked on OCTREOSCAN at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on OCTREOSCAN offers exposure to specialized radiopharmaceutical commercialization, reimbursement strategy for diagnostic imaging agents, and healthcare economics in oncology. However, the LOE-approaching lifecycle and zero current job openings signal limited hiring momentum and career advancement opportunity; roles will emphasize defensive strategy and market share protection rather than growth initiatives.